Literature DB >> 11498723

Opposite effects of nefazodone in two human models of anxiety.

M Silva1, L A Hetem, F S Guimarães, F G Graeff.   

Abstract

RATIONALE AND
OBJECTIVES: To explore further the role of serotonin (5-HT) in anxiety, the effects of the 5-HT reuptake inhibitor and 5-HT2A receptor antagonist nefazodone (NF) were measured in two human models of anxiety.
METHODS: Twenty-nine adult healthy volunteers of both sexes underwent conditioning of skin conductance responses (CSCR) to a tone associated to an aversive white noise. Another 34 subjects performed a simulated public speaking (SPS) task, seemingly related to unconditioned fear. In both tests, subjective states were evaluated through the visual analogue mood scale (VAMS) and a bodily symptoms scale (BSS). In each experiment, subjects were randomly divided into three groups, which received 100 mg NF, 200 mg NF or placebo under double-blind condition.
RESULTS: In the CSCR test, NF decreased the number of spontaneous fluctuations of skin conductance (F=4.94; df=2,26; P=0.015). In addition, the increase in VAMS anxiety factor induced by the conditioning task was attenuated by NF (F=11.11; df=2,26; P<0.001). In contrast, the rise of VAMS anxiety induced by SPS was enhanced by NF (F=8.01; df=2,31; P=0.002).
CONCLUSIONS: These results indicate that NF decreases conditioned anxiety, while enhancing unconditioned fear. Since the effects of NF may be due to impairment of 5-HT neurotransmission, consequent to overstimulation of autosomic 5-HT1A receptors and blockade of post-synaptic 5-HT2A receptors, the present results support the hypothesis that 5-HT facilitates conditioned anxiety, which may be related to generalised anxiety disorder, while inhibiting unconditioned fear, supposedly related to panic disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498723     DOI: 10.1007/s002130100752

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  Impaired recognition of fear facial expressions in 5-HTTLPR S-polymorphism carriers following tryptophan depletion.

Authors:  Abigail A Marsh; Elizabeth C Finger; Beata Buzas; Niveen Soliman; Rebecca A Richell; Meena Vythilingham; Daniel S Pine; David Goldman; R J R Blair
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

2.  Tryptophan depletion decreases the recognition of fear in female volunteers.

Authors:  C J Harmer; R D Rogers; E Tunbridge; P J Cowen; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  2003-04-04       Impact factor: 4.530

Review 3.  Pharmacological challenge studies with acute psychosocial stress.

Authors:  Kathryne Van Hedger; Anya K Bershad; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2017-08-22       Impact factor: 4.905

4.  Modelling anxiety in humans for drug development.

Authors:  Martin Siepmann; Peter Joraschky
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

Review 5.  The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis.

Authors:  Marco Sarchiapone; Carla Gramaglia; Miriam Iosue; Vladimir Carli; Laura Mandelli; Alessandro Serretti; Debora Marangon; Patrizia Zeppegno
Journal:  BMC Psychiatry       Date:  2018-01-25       Impact factor: 3.630

Review 6.  Panic disorder: is the PAG involved?

Authors:  Cristina Marta Del-Ben; Frederico Guilherme Graeff
Journal:  Neural Plast       Date:  2009-03-10       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.